Compare VRME & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRME | IMNN |
|---|---|---|
| Founded | 1999 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2M | 9.1M |
| IPO Year | 2013 | 2000 |
| Metric | VRME | IMNN |
|---|---|---|
| Price | $0.65 | $1.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $1.50 | ★ $10.00 |
| AVG Volume (30 Days) | 45.2K | ★ 94.9K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $16,398,000.00 | N/A |
| Revenue This Year | $36.85 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.59 | $1.39 |
| 52 Week High | $1.51 | $5.71 |
| Indicator | VRME | IMNN |
|---|---|---|
| Relative Strength Index (RSI) | 49.89 | 34.46 |
| Support Level | $0.61 | N/A |
| Resistance Level | $0.74 | $2.18 |
| Average True Range (ATR) | 0.03 | 0.11 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 42.97 | 17.81 |
VerifyMe Inc is a logistics company that specializes in time and temperature-sensitive products, as well as providing brand protection and enhancement solutions. The company operates through two reportable business segments: Precision Logistics offers a value-added service provider for time and temperature-sensitive parcel management. Using a proprietary IT platform, it provides real-time information and analysis to mitigate supply chain flow interruption, delivering last-mile resolution for key markets, including the perishable healthcare and food industries; and the Authentication segment specializes in anti-counterfeit and brand protection. The Precision Logistics segment derives the majority of the revenue.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.